FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1991297890> ?p ?o ?g. }

• W1991297890 endingPage "46" @default.
• W1991297890 startingPage "32" @default.
• W1991297890 abstract "The development of a probabilistic Markov model with a time horizon of 1 year to compare the cost-effectiveness of three bronchodilators: 1) the new long-acting anticholinergic tiotropium; 2) the short-acting anticholinergic ipratropium; and 3) the long-acting beta 2-agonist salmeterol, for the treatment of patients with chronic obstructive pulmonary disease (COPD) in different countries. In this article we compare The Netherlands and Canada.The Markov model was structured along disease severity states and exacerbations. Transition probabilities between disease states and exacerbation probabilities were derived from patient-level data from six randomized controlled trials assessing the efficacy and safety of tiotropium. Resource utilization during exacerbations and maintenance treatment for The Netherlands were derived from two clinical trials, whereas for Canada these data were obtained from a countrywide observational study that used similar inclusion criteria as the trials. Second-order Monte Carlo simulations were undertaken in which values were randomly drawn from distributions of these parameters. Outcomes of the model are yearly treatment costs, exacerbations, and quality-adjusted life months.The mean difference in the number of exacerbations was 0.17 (95% uncertainty interval: -0.02-0.37) in favor of tiotropium when compared with salmeterol and the difference between salmeterol and ipratropium was 0.12 (-0.17-0.44) in favor of salmeterol. The number of quality-adjusted life months did not substantially differ between treatment groups and varied from 8.42 (SE 0.41) in the tiotropium group to 8.17 (0.46) in the salmeterol group and 8.11 (0.50) in the ipratropium group. In The Netherlands, costs in the tiotropium group were 42 Euros (-484-353) lower than in the salmeterol group, whereas costs in the salmeterol group were 128 Euros (-795-457) lower than in the ipratropium group. In Canada, costs were consistently lower than in The Netherlands and nearly the same in all treatment groups. Differences between the two countries were primarily a result of a higher length of hospital stay in case of an exacerbation in The Netherlands. The cost-effectiveness acceptability frontier of exacerbations showed that tiotropium was associated with the maximum expected net benefit for all values of the ceiling ratio above 0 Euros (The Netherlands) and 10 Euros (Canada) in the base case analysis.This probabilistic model-based economic evaluation demonstrates how clinical trial data can be combined and integrated with country-specific information about resource utilization and unit cost to assess the cost-effectiveness of bronchodilators in COPD patients. Quality-adjusted life months did not substantially differ between treatment groups. In terms of exacerbations, tiotropium was associated with maximum expected net benefit for plausible values of the ceiling ratio. In sensitivity analyses, this outcome was most sensitive to changes in exacerbation rates." @default.
• W1991297890 created "2016-06-24" @default.
• W1991297890 creator A5005489200 @default.
• W1991297890 creator A5010272673 @default.
• W1991297890 creator A5035835345 @default.
• W1991297890 creator A5084041755 @default.
• W1991297890 date "2005-01-01" @default.
• W1991297890 modified "2023-10-16" @default.
• W1991297890 title "Probabilistic Markov Model to Assess the Cost-Effectiveness of Bronchodilator Therapy in COPD Patients in Different Countries" @default.
• W1991297890 cites W1547243644 @default.
• W1991297890 cites W1899678835 @default.
• W1991297890 cites W1973742535 @default.
• W1991297890 cites W2004345154 @default.
• W1991297890 cites W2010368883 @default.
• W1991297890 cites W2012968700 @default.
• W1991297890 cites W2019547623 @default.
• W1991297890 cites W2023049016 @default.
• W1991297890 cites W2061382057 @default.
• W1991297890 cites W2065478501 @default.
• W1991297890 cites W2068407303 @default.
• W1991297890 cites W2073166736 @default.
• W1991297890 cites W2076898808 @default.
• W1991297890 cites W2099143922 @default.
• W1991297890 cites W2106203584 @default.
• W1991297890 cites W2107045802 @default.
• W1991297890 cites W2117837864 @default.
• W1991297890 cites W2118269576 @default.
• W1991297890 cites W2120365726 @default.
• W1991297890 cites W2137005037 @default.
• W1991297890 cites W2137457973 @default.
• W1991297890 cites W2139347600 @default.
• W1991297890 cites W2146257741 @default.
• W1991297890 cites W2149199480 @default.
• W1991297890 cites W2158985195 @default.
• W1991297890 cites W2168046003 @default.
• W1991297890 cites W4229694820 @default.
• W1991297890 cites W4239080780 @default.
• W1991297890 doi "https://doi.org/10.1111/j.1524-4733.2005.03086.x" @default.
• W1991297890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15841892" @default.
• W1991297890 hasPublicationYear "2005" @default.
• W1991297890 type Work @default.
• W1991297890 sameAs 1991297890 @default.
• W1991297890 citedByCount "101" @default.
• W1991297890 countsByYear W19912978902012 @default.
• W1991297890 countsByYear W19912978902013 @default.
• W1991297890 countsByYear W19912978902014 @default.
• W1991297890 countsByYear W19912978902015 @default.
• W1991297890 countsByYear W19912978902016 @default.
• W1991297890 countsByYear W19912978902017 @default.
• W1991297890 countsByYear W19912978902018 @default.
• W1991297890 countsByYear W19912978902019 @default.
• W1991297890 countsByYear W19912978902020 @default.
• W1991297890 countsByYear W19912978902021 @default.
• W1991297890 countsByYear W19912978902022 @default.
• W1991297890 countsByYear W19912978902023 @default.
• W1991297890 crossrefType "journal-article" @default.
• W1991297890 hasAuthorship W1991297890A5005489200 @default.
• W1991297890 hasAuthorship W1991297890A5010272673 @default.
• W1991297890 hasAuthorship W1991297890A5035835345 @default.
• W1991297890 hasAuthorship W1991297890A5084041755 @default.
• W1991297890 hasBestOaLocation W19912978901 @default.
• W1991297890 hasConcept C126322002 @default.
• W1991297890 hasConcept C159110408 @default.
• W1991297890 hasConcept C168563851 @default.
• W1991297890 hasConcept C177713679 @default.
• W1991297890 hasConcept C1862650 @default.
• W1991297890 hasConcept C2776042228 @default.
• W1991297890 hasConcept C2776719499 @default.
• W1991297890 hasConcept C2776780178 @default.
• W1991297890 hasConcept C2776968687 @default.
• W1991297890 hasConcept C2777014857 @default.
• W1991297890 hasConcept C2777714996 @default.
• W1991297890 hasConcept C2778689640 @default.
• W1991297890 hasConcept C2779951463 @default.
• W1991297890 hasConcept C2781018748 @default.
• W1991297890 hasConcept C2909577894 @default.
• W1991297890 hasConcept C3018587741 @default.
• W1991297890 hasConcept C71924100 @default.
• W1991297890 hasConceptScore W1991297890C126322002 @default.
• W1991297890 hasConceptScore W1991297890C159110408 @default.
• W1991297890 hasConceptScore W1991297890C168563851 @default.
• W1991297890 hasConceptScore W1991297890C177713679 @default.
• W1991297890 hasConceptScore W1991297890C1862650 @default.
• W1991297890 hasConceptScore W1991297890C2776042228 @default.
• W1991297890 hasConceptScore W1991297890C2776719499 @default.
• W1991297890 hasConceptScore W1991297890C2776780178 @default.
• W1991297890 hasConceptScore W1991297890C2776968687 @default.
• W1991297890 hasConceptScore W1991297890C2777014857 @default.
• W1991297890 hasConceptScore W1991297890C2777714996 @default.
• W1991297890 hasConceptScore W1991297890C2778689640 @default.
• W1991297890 hasConceptScore W1991297890C2779951463 @default.
• W1991297890 hasConceptScore W1991297890C2781018748 @default.
• W1991297890 hasConceptScore W1991297890C2909577894 @default.
• W1991297890 hasConceptScore W1991297890C3018587741 @default.
• W1991297890 hasConceptScore W1991297890C71924100 @default.
• W1991297890 hasIssue "1" @default.
• W1991297890 hasLocation W19912978901 @default.
• W1991297890 hasLocation W19912978902 @default.

• next